Literature DB >> 10582980

Stroke treatment economic model (STEM): predicting long-term costs from functional status.

J J Caro1, K F Huybrechts.   

Abstract

BACKGROUND AND
PURPOSE: Stroke is a debilitating disease with long-term social and economic consequences. As new therapies for acute ischemic stroke are forthcoming, there is an increasing need to understand their long-term economic implications. To address this need, a stroke economic model was created.
METHODS: The model consists of 3 modules. A short-term module incorporates short-term clinical trial data. A long-term module composed of several Markov submodels predicts patient transitions among various locations over time. The modules are connected via a bridge component that groups the survivors at the end of the short-term module according to their functional status and location. Examples of analyses that can be conducted with this model are provided with the use of data from 2 international trials. For illustration, UK unit costs were estimated.
RESULTS: With the trial data in the short-term module, the short-term management cost is estimated to be pound8326 (US $13,649 [USD]). Hospital stay was the major cost driver. By the end of the trials, there was a pronounced difference in the distribution of patient locations between functional groups. It is predicted in the long-term module that the subsequent cost amounts to pound75 985 (124,564 USD) for a major and pound27,995 (45,893 USD) for a minor stroke.
CONCLUSIONS: Linking functional recovery at the end of short-term treatment with patients' treatment and residential locations allows this model to estimate the long-term economic impact of stroke interventions. Using patient location instead of the more common natural history as the model foundation allows quantification of the long-term impact to become data driven and hence increases confidence in the results.

Entities:  

Mesh:

Year:  1999        PMID: 10582980     DOI: 10.1161/01.str.30.12.2574

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

1.  Functional Impairment: An Unmeasured Marker of Medicare Costs for Postacute Care of Older Adults.

Authors:  S Ryan Greysen; Irena Stijacic Cenzer; W John Boscardin; Kenneth E Covinsky
Journal:  J Am Geriatr Soc       Date:  2017-06-21       Impact factor: 5.562

2.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2011-06-01       Impact factor: 6.829

Review 4.  A benefit-risk assessment of agents used in the secondary prevention of stroke.

Authors:  Ronald S MacWalter; Colin P Shirley
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Continuous monitoring of changes in plasma nitrite following cerebral ischemia in a rabbit embolic stroke model.

Authors:  James H Silver; Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2011-06       Impact factor: 6.829

6.  A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.

Authors:  Denise M Boudreau; Greg Guzauskas; Kathleen F Villa; Susan C Fagan; David L Veenstra
Journal:  Ann Emerg Med       Date:  2012-05-24       Impact factor: 5.721

7.  The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.

Authors:  Patrick W Sullivan; Thomas W Arant; Samuel L Ellis; Heather Ulrich
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke).

Authors:  Theresa I Shireman; Kaijun Wang; Jeffrey L Saver; Mayank Goyal; Alain Bonafé; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Reza Jahan; Katherine A Vilain; John House; Jin-Moo Lee; David J Cohen
Journal:  Stroke       Date:  2016-12-27       Impact factor: 7.914

Review 9.  Long term cost-of-illness in stroke: an international review.

Authors:  Krista A Payne; Krista F Huybrechts; J Jaime Caro; Traci J Craig Green; Wendy S Klittich
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  The economic burden of stroke in the United Kingdom.

Authors:  Penny Youman; Koo Wilson; Farzaneh Harraf; Lalit Kalra
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.